- Home
- ET vs ALNY Comparison
ET vs ALNY Comparison
Compare ET & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ET | ALNY |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.5B | 52.9B |
| IPO Year | 2006 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ET | ALNY |
|---|---|---|
| Price | $16.51 | $401.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 28 |
| Target Price | $21.62 | ★ $479.45 |
| AVG Volume (30 Days) | ★ 13.4M | 1.7M |
| Earning Date | 02-10-2026 | 02-12-2026 |
| Dividend Yield | ★ 8.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.25 | 0.33 |
| Revenue | ★ $79,757,000,000.00 | $3,210,070,000.00 |
| Revenue This Year | $3.55 | $70.04 |
| Revenue Next Year | $12.36 | $43.08 |
| P/E Ratio | ★ $13.17 | $1,205.90 |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $14.60 | $205.87 |
| 52 Week High | $21.45 | $495.55 |
Technical Indicators
Market Signals| Indicator | ET | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 40.06 |
| Support Level | $16.18 | $393.64 |
| Resistance Level | $16.55 | $404.58 |
| Average True Range (ATR) | 0.18 | 10.41 |
| MACD | 0.01 | 0.77 |
| Stochastic Oscillator | 64.89 | 50.42 |
Price Performance
Historical ComparisonAbout ET Energy Transfer LP
Energy Transfer is a diversified midstream firm, operating from wellhead to consuming demand. It handles natural gas, natural gas liquids(NGLs), crude oil, and refined products. Commodities are moved through its network of field level gathering and processing to refineries and demand centers. Operations are concentrated in Texas and the Midcontinent United States. It also controls Sunoco and USA Compression through its general partner relationship.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.